Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. - Wikidata - awgldk - TriplyDB

Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.

Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.

http://www.wikidata.org/entity/Q45779809

about

Juvenile Idiopathic Arthritis: Diagnosis and Treatment An important complication of a child with juvenile idiopathic arthritis: macrophage activation syndrome.Juvenile Idiopathic Arthritis 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening a Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Childr Polyarticular juvenile idiopathic arthritis - epidemiology and management approaches Correlation analyses of clinical and molecular findings identify candidate biological pathways in systemic juvenile idiopathic arthritis Lipid profiles alter from pro-atherogenic into less atherogenic and proinflammatory in juvenile idiopathic arthritis patients responding to anti TNF-α treatment.The development and assessment of biological treatments for children.Do patients with juvenile idiopathic arthritis in clinical remission have evidence of persistent inflammation on 3T magnetic resonance imaging?Juvenile spondyloarthritis.MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.Emerging drugs for Duchenne muscular dystrophy Evaluation and Treatment of Childhood Enthesitis-Related Arthritis.Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Update on the treatment of juvenile idiopathic arthritis Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis.Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature.Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept Update on juvenile spondyloarthritis.Clinical utility of etanercept in the treatment of arthritides in children and adolescents.Biological agents for the treatment of uveitis.Update on biologicals for treatment of juvenile idiopathic arthritis.Etanercept (Enbrel) in the treatment of juvenile idiopathic arthritis.Etanercept: a review of its use in autoimmune inflammatory diseases.Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations.Treatment response to etanercept in methotrexate refractory juvenile idiopathic arthritis: an analysis of predictors and long-term outcomes.Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept.[Evidence of treatment of chronic inflammation in childhood and adolescence with biologics].Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.[Biologics register JuMBO. Long-term safety of biologic therapy of juvenile idiopathic arthritis].US trends in rates of arthroplasty for inflammatory arthritis including rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritis.Delineating the role of multiple intraarticular corticosteroid injections in the management of juvenile idiopathic arthritis in the biologic era.Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy.Anticarbamylated protein (anti-CarP) antibodies are present in sera of juvenile idiopathic arthritis (JIA) patients.S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis.Achievement of clinical remission in patients with juvenile idiopathic arthritis under a 2-10-year Etanercept exposure.Low pretreatment levels of myeloid-related protein-8/14 and C-reactive protein predict poor adherence to treatment with tumor necrosis factor inhibitors in juvenile idiopathic arthritis.Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.

P2860

Q28079246-9478FA72-3618-44D3-BD0E-446D3C512889 Q33410259-A4D2E1B2-D187-46D5-983D-BBB8F3929B0A Q33572045-F6F73988-AB93-4A7E-8074-375DF312B884 Q33613293-A6EB5ED7-3B82-45CE-8FB0-768E3266A17D Q33801499-DDF48A7C-C3FC-4D98-9C68-73D2295C78F3 Q34434750-93800A42-8D95-4B9E-9349-29F4D0EBDCCB Q34455674-AD5E4BB7-3463-42D2-A0F0-1DC3452E4703 Q35112757-AFF4EFEF-EEE3-47BC-9371-8D3725A2F4D3 Q35135936-70486894-96B7-4819-9092-505E9300D1AA Q35431243-D0DC64F6-9DDA-4E00-B4FA-653045798DD5 Q35800954-2CC516AD-538C-47EF-9A62-07899BDBE37B Q35926593-383C87DD-0057-43F8-BFA9-DFC589C463EC Q36363716-A4DF3720-9301-47DE-AD90-2E2B9F4D0EC2 Q36498631-CE4EE0B5-CC03-485E-9785-DD3F30B38ED1 Q36795982-998B236E-6414-4D0B-A034-B06F5C282C55 Q37060351-397BE077-1C3A-41A5-8E7F-32FDDCE644E8 Q37343947-4B046B12-583D-4D63-8C7C-F53917A9B8A4 Q37463702-65E54EB4-1A27-447C-A50C-C14ED54D5229 Q37518319-651E788A-5B0C-4205-82B8-E645CF7C5778 Q37598921-575EFF61-688B-4612-8821-109C7443ACB6 Q37676020-3E068194-1B20-4841-8B2A-76AF713035CC Q37984565-91FBF8F6-753D-484D-9370-D2E1F413C351 Q38071693-EC16C641-A664-4347-B9DA-9DD279A193CA Q38144094-B4D2CCD1-0785-4DD3-92FE-4D01C89A1F6D Q38230740-1A533E5F-859E-45ED-94BC-1CB9A374061A Q38406386-6F6AAA71-E294-4370-A9B9-06F27B89051A Q38765960-96B348ED-1748-47C1-BE65-FADA8EFAD6BC Q40133584-EFD7AAE0-872C-4D4C-BD31-547724F93F08 Q40179129-92B53F4B-7FC8-4E92-B7E7-03D0215641F7 Q40995768-D3A9A484-7B3C-4548-913B-D8A0A854DA10 Q43689633-01A604BB-B83D-4269-91FF-004983820E01 Q44503376-0B50AFCC-781F-40E2-917E-164AC02F1ACE Q45247787-AD0C8FE0-E62E-46D0-AC24-FC68D6728BEE Q45348883-F3BA843E-0AAF-4700-8C10-55DBA2E6EAF0 Q45975049-37BDC91E-3F90-413A-B3A5-0B42F319D552 Q47965354-0547FC68-A96D-4464-AF99-548E7F232B4D Q48262195-AC8C7E0B-1313-4062-A254-33281F6A5D27 Q51055393-CB8F7910-CCAB-498F-A9A6-D17558D93B35 Q51550151-32D47FC2-E65A-45E7-91A2-FA0274EF82D6 Q51740150-464614C0-D562-41B4-BF48-6732456E4273

P2860

Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.

http://www.wikidata.org/entity/Q45779809

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Factors associated with treatm ...... juvenile idiopathic arthritis.

@en

Factors associated with treatm ...... juvenile idiopathic arthritis.

@nl

type

label

Factors associated with treatm ...... juvenile idiopathic arthritis.

@en

Factors associated with treatm ...... juvenile idiopathic arthritis.

@nl

prefLabel

Factors associated with treatm ...... juvenile idiopathic arthritis.

@en

Factors associated with treatm ...... juvenile idiopathic arthritis.

@nl

P1433

Q45779809-28F4924E-8F29-4D95-9431-5AE24F25A7AA

P1476

Q45779809-722FB552-5FA2-4262-BD70-C5CFA2BE8C63

P2093

Q45779809-098F489D-79F6-4B90-B931-591DD0246EBF

Q45779809-1D04701F-FC07-4A9B-A094-A288C3257748

Q45779809-31344B8E-8B94-474B-A0B5-B2F0D74BAF62

Q45779809-461FEE6E-C8C4-477B-8FDF-89FFAB473B7E

Q45779809-4D1F4E76-5A80-47D8-B4AE-F38BBB37318D

Q45779809-60B4AA17-3C07-41A6-92B4-F7B9FB60DD1E

Q45779809-94547AE0-8D5B-415B-BA0B-F7A573D80E9F

Q45779809-9871A817-792E-441C-8303-7A953A5D5BB7

Q45779809-A89866CF-FE92-48A2-A250-0AC43D3A6DEA

Q45779809-D0C7D854-6FB7-41C0-93F8-EB1A71F07179

P304

Q45779809-69201D65-5A18-45E5-AFCC-A389F8BF7A09

P31

Q45779809-C257BC8E-DD7F-412C-9243-2D9C896214FF

P356

Q45779809-48680A1A-C891-4407-AA6B-069D8125FFEF

P407

Q45779809-CED3CFBE-7F3E-46E1-BFFB-278D315E6991

P433

Q45779809-6FDE4403-9A19-4998-9982-C7CB029CF953

P478

Q45779809-A8C50724-9DDD-4499-AB70-C117FBBC68CF

P577

Q45779809-1A022B60-F7B6-4ADE-9043-7101C8F18437

P5875

Q45779809-766C2BD4-04A0-4D25-A4C7-F0D38DA68C34

P698

Q45779809-8E5B7EC2-0976-4F98-BFEA-60CF6105200D

P921

Q45779809-5931E175-692D-4846-B0E7-664FD90D5CD8

P356

P1433

Journal of the American Medical Association

P1476

Factors associated with treatm ...... juvenile idiopathic arthritis.

@en

P2093

Esther P A H Hoppenreijs

http://www.w3.org/2001/XMLSchema#string

Femke H M Prince

http://www.w3.org/2001/XMLSchema#string

J Merlijn van den Berg

http://www.w3.org/2001/XMLSchema#string

Joost F Swart

http://www.w3.org/2001/XMLSchema#string

Koert M Dolman

http://www.w3.org/2001/XMLSchema#string

Lisette W A van Suijlekom-Smit

http://www.w3.org/2001/XMLSchema#string

Marieke H Otten

http://www.w3.org/2001/XMLSchema#string

Marinka Twilt

http://www.w3.org/2001/XMLSchema#string

Marion A J van Rossum

http://www.w3.org/2001/XMLSchema#string

Nico M Wulffraat

http://www.w3.org/2001/XMLSchema#string

P304

2340-2347

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.2011.1671

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

306

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51772877

http://www.w3.org/2001/XMLSchema#string

P698

22056397

http://www.w3.org/2001/XMLSchema#string

P921

juvenile rheumatoid arthritis